UK pharma major GSK (LSE: GSK) and US biotech SpringWorks Therapeutics (Nasdaq: SWTX) are to end their collaboration combining Blenrep (belantamab mafodotin) and Ogsiveo (nirogacestat).
The companies were hoping that GSK’s BCMA-targeting antibody-drug conjugate Blenrep and SpringWorks’ oral gamma secretase inhibitor Ogsiveo would work in multiple myeloma, and agreed to combine them in a global, non-exclusive license and collaboration agreement.
GSK and SpringWorks first started working together on the pairing in 2019 - later amending this collaboration in 2021 - in patients with relapsed or refractory multiple myeloma. The expanded agreement that was signed in 2022 allowed for studying the combination in earlier lines of treatment, including newly-diagnosed patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze